Li LJ, et al. - Researchers analyzed relevant trials to assess the overall risk and incidence of thromboembolism with bevacizumab (a recombinant humanized monoclonal antibody against vascular endothelial growth factor) in non-small cell lung cancer (NSCLC) patients. They analyzed a total of 3,555 subjects from nine studies. They used either random-effect or fixed-effect models, depending on the heterogeneity, to calculate the overall incidence rates, odds ratios, and 95% confidence intervals via statistical analyses. Trial sequence analysis was also used to verify the pooled result. Findings revealed a significantly increased risk of thromboembolism development in association with treatment with bevacizumab in NSCLC patients. It could have a dose-toxicity relationship. When used in low dose, bevacizumab offered equal efficacy and low hazard of thromboembolism events and hence, could be a better choice for NSCLC patients.